アクセス数 : ?
ダウンロード数 : ?
ID 109985
タイトル別表記
転移性大腸癌に対する2次治療としてのIRIS+panitumumab療法の有効性の検討
IRIS plus panitumumab for metastatic CRC
著者
髙岡, 遠 徳島大学大学院医科学教育部(医学専攻)
Shimoyama, Rai Shonan Kamakura General Hospital
Kawamoto, Shunji Fukuoka Tokushukai Medical Center
Sakamoto, Kazuki Kishiwada Tokushukai Hospital
Goda, Fuminori Kagawa University Hospital
Negoro, Yuji Kochi Health Sciences center
Tsuji, Akihito Kobe City Medical Center General Hospital
Yoshizaki, Koji Sapporo Higashi Tokushukai Hospital
矢野, 弘美 Tokushima University
木村, 雅子 Tokushima University
Niitsu, Yoshiro Sapporo Medical University
キーワード
colorectal cancer
IRIS
panitumumab
second-line therapy
chemotherapy
irinotecan
S-1
資料タイプ
学位論文
抄録
Background Irinotecan plus S-1 (IRIS) is the only oral fluoropyrimidine-based regimen reported to be non-inferior to FOLFIRI and widely used in clinical practice for metastatic colorectal cancer (mCRC) patients. However, the combination of IRIS plus an anti-EGFR agent has not been evaluated previously. This study aimed to investigate the feasibility and efficacy of IRIS with panitumumab as second-line therapy for wild-type KRAS mCRC.
Methods Main inclusion criteria were patients with wild-type KRAS mCRC refractory to one prior chemotherapy regimen for mCRC, ECOG PS 0-2, and age ≥ 20 years. Patients received panitumumab (6mg/kg) and irinotecan (100mg/m2) on days 1 and 15 and S-1 (40-60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks. The primary endpoint was the feasibility of the therapy. The secondary endpoints were response rate (RR), progression-free survival (PFS), and overall survival (OS).
Results A total of 36 patients received protocol treatment in eight centers. Of these, 23 patients (63.9%) completed protocol treatment, demonstrating achievement of the primary endpoint. The most frequent grade 3/4 toxicities were diarrhea (16.7%), acne-like rash (13.9%), and neutropenia (11.1%). The overall RR was 33.3% (12/36). Of these 4 five underwent conversion surgery. Median PFS and OS were 9.5 months (95% CI 3.5-15.4 months) and 20.1 months (95% CI 16.7-23.2 months), respectively.
Conclusion IRIS plus panitumumab has an acceptable toxicity profile and a promising efficacy in patients with previously treated wild-type KRAS mCRC. Accordingly, this regimen can be an additional treatment option for second-line chemotherapy in wild-type KRAS mCRC.
掲載誌名
Cancer Chemotherapy and Pharmacology
ISSN
03445704
14320843
cat書誌ID
AA00598397
AA1161885X
出版者
Springer Berlin Heidelberg
78
2
開始ページ
397
終了ページ
403
発行日
2016-06-24
備考
内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨 : LID201701051002.pdf
論文本文 : k2997_fulltext.pdf
著者の申請により要約(2017-01-05公開)に替えて論文全文を公開(2019-04-23)
本論文は, 著者Toshi Takaokaの学位論文として提出され, 学位審査・授与の対象となっている。
権利情報
The final publication is available at link.springer.com.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
博士論文全文を含む
文科省報告番号
甲第2997号
学位記番号
甲医第1302号
学位授与年月日
2016-10-27
学位名
博士(医学)
学位授与機関
徳島大学
部局
医学系
病院